The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
Many families with multiple cases of ovarian cancer, breast cancer, or both segregate inherited mutations in one allele of the tumor suppressor gene BRCA1. Genetic testing is used to assess cancer risk; however, testing can detect missense DNA alterations, called unclassified variants, of unknown functional and biological significance with uncertain risk implications. Some missense variants at the transcriptional activation domain of BRCA1 of cancer patients inactivate transcriptional activity of BRCA1, providing evidence that they are deleterious. We identified the variants V1804D and M1628T at the transcriptional activation domain of BRCA1 of two ovarian cancer patients without a family history of ovarian or breast cancer. To test if these residues are critical for transcriptional activation, we created V1804D and M1628T independently in BRCA1 cDNA via site-directed mutagenesis in a mammalian expression vector, pcDNA3.1. Wild-type, mutant, and empty vector constructs were tested in human kidney 293 cells using a p53-responsive luciferase reporter. M1628T had the same transcriptional activity as wild-type BRCA1 but V1804D and the empty vector control showed a 60% reduction. This indicates that V1804D is deleterious but M1628T is not.
Ostrow
Kimberly Laskie
KL
Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
McGuire
Valerie
V
Whittemore
Alice S
AS
DiCioccio
Richard A
RA
D019943:Amino Acid Substitution; D019313:BRCA1 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics; D016022:Case-Control Studies; D004252:DNA Mutational Analysis / Q000379:methods; D005260:Female; D017930:Genes, Reporter; D014644:Genetic Variation / Q000235:genetics; D006801:Humans; D008156:Luciferases / Q000235:genetics; D020125:Mutation, Missense / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics; D014158:Transcription, Genetic / Q000235:genetics*
D019313:BRCA1 Protein; D008156:Luciferases